Research on a treatment for neuroblastoma has shown promise, with a molecule referred to as a "molecular glue" appearing to harness the immune system to target the cancer. The treatment, involving an RBM39 degrader, may be effective despite the ability of cancer cells to change and adapt. Studies on the topic have been published, exploring the molecular and genetic aspects of neuroblastoma and potential therapeutic approaches.